Chantal M.
- Country
- Belgium
- Department
- Endocrinology
Research Overview
- Exposure-Response Study of Siplizumab in Adults with New Onset Type 1 Diabetes: A 12-Month, Randomized, Single-Blind, Placebo-Controlled Trial
- Long-term Verapamil Hydrochloride Therapy in Type 1 Diabetes Mellitus: A Multi-Center Study on Beta-Cell Function Preservation
- Evaluation of Verapamil Hydrochloride on Beta-Cell Function Preservation in Adults with Newly Diagnosed Type 1 Diabetes Mellitus
Data & Insights
Has run more than one trial at 19 of 94 partner sites.
Specializations
Diabetes Management
This investigator specializes in Type 1 diabetes mellitus (T1D) research, with particular emphasis on preserving and evaluating beta-cell function in adult patients.
- Beta-cell preservation strategies
- Long-term therapeutic interventions
- Novel treatment approaches
The research focus includes monitoring disease progression through C-peptide response assessments.
Therapeutic Innovation
The investigator explores innovative treatment modalities, including Verapamil SR therapy and siplizumab for diabetes management.
- Medication efficacy studies
- Treatment response evaluation
- Long-term therapeutic outcomes
Research activities center on evaluating therapeutic interventions in both newly diagnosed and established T1D cases.
Clinical Assessment Methods
Expertise in implementing sophisticated clinical assessment techniques, particularly the mixed-meal tolerance test (MMTT) for evaluating diabetes treatment efficacy.
- Metabolic response monitoring
- Longitudinal patient assessment
- Therapeutic response markers
Focus includes systematic evaluation of treatment outcomes through standardized clinical protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.